Cite

HARVARD Citation

    Kassir, N. et al. (2022). Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis. CPT: pharmacometrics & systems pharmacology. pp. 1234-1243. [Online]. 
  
Back to record